Intellia Therapeutics Plunges 12.42% on Phase 3 Trial Update

In pre-market trading on May 29, 2025, Intellia Therapeutics shares fell sharply, dropping 12.42%, as investors reacted to recent updates on its clinical trial progress.

The decline followed an announcement regarding its Phase 3 study evaluating NTLA-2001 (formerly known as “nex-z”) for transthyretin cardiac amyloidosis (ATTR-CM). While specifics of the update were not disclosed, such late-stage trial developments often influence regulatory and commercial prospects, prompting market caution. ATTR-CM is a progressive heart condition, and the therapy’s performance in pivotal trials has been critical to its potential approval and adoption.

Broad market trends showed mixed activity, with semiconductor stocks rising on optimism around AI infrastructure demand. However, Intellia’s stumble contrasted with sector gains, underscoring its reliance on clinical data milestones. The company’s stock has historically been volatile, tied closely to trial outcomes and regulatory feedback for its gene-editing therapies.